Impact of Empirical Antimicrobial Treatment on Patients with Ventilator-Associated Pneumonia Due to Stenotrophomonas maltophilia

Bibliographic Details
Title: Impact of Empirical Antimicrobial Treatment on Patients with Ventilator-Associated Pneumonia Due to Stenotrophomonas maltophilia
Authors: Pirawan Khunkit, Pisud Siripaitoon, Yongyut Lertsrisatit, Dissaya Watthanapaisal, Narongdet Kositpantawong, Siripen Kanchanasuwan, Nadia Cheh-oh, Sorawit Chittrakarn, Tanapat Jaroenmark, Natnicha Poonchuay, Sarunyou Chusri
Source: Antibiotics, Vol 13, Iss 8, p 729 (2024)
Publisher Information: MDPI AG, 2024.
Publication Year: 2024
Collection: LCC:Therapeutics. Pharmacology
Subject Terms: antimicrobial treatment, ventilator-associated pneumonia, S. maltophilia, Therapeutics. Pharmacology, RM1-950
More Details: This retrospective study was conducted to evaluate the characteristics and outcomes of patients with ventilator-associated pneumonia (VAP) caused by Stenotrophomonas maltophilia (S. maltophilia), focusing on the impact of appropriate empirical antimicrobial treatment. Of the enrolled 240 patients with VAP due to S. maltophilia (median age: 45 years) in a tertiary-care hospital in southern Thailand between January 2010 and December 2021, 90% had medical comorbidities and 91% had previously received carbapenems. In addition, only 45% of the patients were initially admitted to the intensive care unit. Patients administered appropriate empirical antimicrobial treatment including colistin alone and colistin plus TMP-SMX or fluoroquinolone-based regimens had significantly lower 14-day, 30-day, and in-hospital mortalities, compared with those who did not receive appropriate empirical antimicrobial treatment (21% and 2% vs. 31%; 30% and 5% vs. 44%; and 30% and 12% vs. 53%, respectively). Thus, the use of appropriate empirical antimicrobial treatments led to a significantly reduced length of hospital stay, duration of ventilation, and hospital costs. The current study suggests that the use of appropriate empirical antimicrobial treatment based on susceptibility testing without considering pharmacokinetic properties and administration dosages improves the outcomes of patients with VAP due to S. maltophilia.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 2079-6382
Relation: https://www.mdpi.com/2079-6382/13/8/729; https://doaj.org/toc/2079-6382
DOI: 10.3390/antibiotics13080729
Access URL: https://doaj.org/article/30a574fc46cc4145b9f83c865e0503d1
Accession Number: edsdoj.30a574fc46cc4145b9f83c865e0503d1
Database: Directory of Open Access Journals
More Details
ISSN:20796382
DOI:10.3390/antibiotics13080729
Published in:Antibiotics
Language:English